SPECIAL ENDOTEXT AND THYROIDMANAGER SYMPOSIUM

TYROSINE KINASE INHIBITORS IN MANAGEMENT OF AGGRESSIVE DIFFERENTIATED THYROID CANCER

CME Credits are available for Symposium readers--Click here--http://www.cvent.com/d/24q4qp

PLEASE  TAKE A SHORT EVALUATION SURVEY AFTER YOU VISIT/READ THIS SYMPOSIUM---CLICK HERE

INTRODUCTION   James Hennessey, MD   Harvard Medical School,  Boston, MA

 S1- CONTEMPORARY MANAGEMENT OF DIFFERENTIATED THYROID CANCER

Furio Pacini, MD Thyroid Unit, University of Siena, Siena Italy

Leslie J De Groot, MD, University of Rhode Island, Providence, RI

S2- DEFINING RAI REFRACTORY THYROID CANCER: WHEN IS RAI THERAPY UNLIKELY TO ACHIEVE A THERAPEUTIC RESPONSE?

R Michael Tuttle, MD  and  Mona M. Sabra, MD

Endocrinology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021

S3- SELECTION OF PATIENTS FOR TYROSINE KINASE INHIBITOR TREATMENT

Furio Pacini, MD Professor of Endocrinology, Director, Section of Endocrinology and Metabolism, University of Siena, Siena, Italy

Martin Schlumberger , MD Professor of Oncology, University of Paris-Sud, Director, Nuclear Medicine and Endocrine Tumors Division, Institut Gustave-Roussy, Villejuif, Paris, France.

S4- NEW TREATMENT ALGORITHMS FOR SYSTEMIC THERAPY WITH TKIs IN MANAGING AGGRESSIVE THYROID CANCER

Joshua Klopper  and  Bryan Haugen

University of Colorado School of Medicine

S5- CHANGING OUTLOOK ON MANAGEMENT OF AGGRESSIVE DIFFERENTIATED CANCER

James Fagin, MD

Organized and edited by James V Hennessey, MD and Leslie J De Groot, MD

AVAILABLE IN SOFT-COVER PRINT FORMAT    AT  AMAZON.COM, AND  AMAZON.CO.UK, (or DE, FR, IT, ES) (Title ID: 4816017) , AND www.createspace.com/4816017    List Price: $15.00
8 x10,  80 pages, ISBN-13: 978-1499618716